These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

117 related articles for article (PubMed ID: 20030297)

  • 61. 3D-QSAR CoMFA/CoMSIA models based on theoretical active conformers of HOE/BAY-793 analogs derived from HIV-1 protease inhibitor complexes.
    da Cunha EF; Sippl W; de Castro Ramalho T; Ceva Antunes OA; de Alencastro RB; Albuquerque MG
    Eur J Med Chem; 2009 Nov; 44(11):4344-52. PubMed ID: 19616874
    [TBL] [Abstract][Full Text] [Related]  

  • 62. Comparative analysis of the surface interaction properties of the binding sites of CDK2, CDK4, and ERK2.
    Kelly MD; Mancera RL
    ChemMedChem; 2006 Mar; 1(3):366-75. PubMed ID: 16892371
    [TBL] [Abstract][Full Text] [Related]  

  • 63. Pyrazolo[3,4-c]pyridazines as novel and selective inhibitors of cyclin-dependent kinases.
    Braña MF; Cacho M; García ML; Mayoral EP; López B; de Pascual-Teresa B; Ramos A; Acero N; Llinares F; Muñoz-Mingarro D; Lozach O; Meijer L
    J Med Chem; 2005 Nov; 48(22):6843-54. PubMed ID: 16250643
    [TBL] [Abstract][Full Text] [Related]  

  • 64. Study of a ligand complexed with Cdk2/Cdk4 by computer simulation.
    Jiang Y; Zou J; Gui C
    J Mol Model; 2005 Nov; 11(6):509-15. PubMed ID: 15928920
    [TBL] [Abstract][Full Text] [Related]  

  • 65. Identification of High-Affinity Inhibitors of Cyclin-Dependent Kinase 2 Towards Anticancer Therapy.
    Mohammad T; Batra S; Dahiya R; Baig MH; Rather IA; Dong JJ; Hassan I
    Molecules; 2019 Dec; 24(24):. PubMed ID: 31847444
    [TBL] [Abstract][Full Text] [Related]  

  • 66. Role of interactions and volume variation in discriminating active and inactive forms of cyclin-dependent kinase-2 inhibitor complexes.
    Saranya N; Selvaraj S
    Chem Biol Drug Des; 2011 Sep; 78(3):361-9. PubMed ID: 21599856
    [TBL] [Abstract][Full Text] [Related]  

  • 67. Explicit treatment of active-site waters enhances quantum mechanical/implicit solvent scoring: Inhibition of CDK2 by new pyrazolo[1,5-a]pyrimidines.
    Hylsová M; Carbain B; Fanfrlík J; Musilová L; Haldar S; Köprülüoğlu C; Ajani H; Brahmkshatriya PS; Jorda R; Kryštof V; Hobza P; Echalier A; Paruch K; Lepšík M
    Eur J Med Chem; 2017 Jan; 126():1118-1128. PubMed ID: 28039837
    [TBL] [Abstract][Full Text] [Related]  

  • 68. Predicting the impact of single-nucleotide polymorphisms in CDK2-flavopiridol complex by molecular dynamics analysis.
    Nagasundaram N; Doss CG
    Cell Biochem Biophys; 2013 Jul; 66(3):681-95. PubMed ID: 23300027
    [TBL] [Abstract][Full Text] [Related]  

  • 69. A computational study of the protein-ligand interactions in CDK2 inhibitors: using quantum mechanics/molecular mechanics interaction energy as a predictor of the biological activity.
    Alzate-Morales JH; Contreras R; Soriano A; Tuñon I; Silla E
    Biophys J; 2007 Jan; 92(2):430-9. PubMed ID: 17085505
    [TBL] [Abstract][Full Text] [Related]  

  • 70. Insights into the structural basis of 3,5-diaminoindazoles as CDK2 inhibitors: prediction of binding modes and potency by QM-MM interaction, MESP and MD simulation.
    Tripathi SK; Singh SK
    Mol Biosyst; 2014 Aug; 10(8):2189-201. PubMed ID: 24909777
    [TBL] [Abstract][Full Text] [Related]  

  • 71. Synthesis and structure of the β-carboline derivatives and their binding intensity with cyclin-dependent kinase 2.
    Wang Y; Jin Q; Lin G; Yang T; Wang Z; Lu Y; Tang Y; Liu L; Lu T
    Chem Pharm Bull (Tokyo); 2012; 60(4):435-41. PubMed ID: 22466726
    [TBL] [Abstract][Full Text] [Related]  

  • 72. MORPH: a new tool for ligand design.
    Beno BR; Langley DR
    J Chem Inf Model; 2010 Jun; 50(6):1159-64. PubMed ID: 20481489
    [TBL] [Abstract][Full Text] [Related]  

  • 73. Mechanistic insights into the phosphoryl transfer reaction in cyclin-dependent kinase 2: A QM/MM study.
    Recabarren R; Osorio EH; Caballero J; Tuñón I; Alzate-Morales JH
    PLoS One; 2019; 14(9):e0215793. PubMed ID: 31483779
    [TBL] [Abstract][Full Text] [Related]  

  • 74. Quantum mechanical scoring: structural and energetic insights into cyclin-dependent kinase 2 inhibition by pyrazolo[1,5-a]pyrimidines.
    Brahmkshatriya PS; Dobeš P; Fanfrlik J; Rezáç J; Paruch K; Bronowska A; Lepšík M; Hobza P
    Curr Comput Aided Drug Des; 2013 Mar; 9(1):118-29. PubMed ID: 23157414
    [TBL] [Abstract][Full Text] [Related]  

  • 75. 8-Substituted O(6)-cyclohexylmethylguanine CDK2 inhibitors: using structure-based inhibitor design to optimize an alternative binding mode.
    Carbain B; Paterson DJ; Anscombe E; Campbell AJ; Cano C; Echalier A; Endicott JA; Golding BT; Haggerty K; Hardcastle IR; Jewsbury PJ; Newell DR; Noble ME; Roche C; Wang LZ; Griffin RJ
    J Med Chem; 2014 Jan; 57(1):56-70. PubMed ID: 24304238
    [TBL] [Abstract][Full Text] [Related]  

  • 76. Comparative analysis of various electrostatic potentials on docking precision against cyclin-dependent kinase 2 protein: a multiple docking approach.
    Tripathi SK; Soundarya RN; Singh P; Singh SK
    Chem Biol Drug Des; 2015 Feb; 85(2):107-18. PubMed ID: 24923208
    [TBL] [Abstract][Full Text] [Related]  

  • 77. Binding free energy estimation for protein-ligand complex based on MM-PBSA with various partial charge models.
    Fu T; Jin Z; Xiu Z; Li G
    Curr Pharm Des; 2013; 19(12):2293-307. PubMed ID: 23082979
    [TBL] [Abstract][Full Text] [Related]  

  • 78. Fusion of Structure and Ligand Based Methods for Identification of Novel CDK2 Inhibitors.
    Mahajan P; Chashoo G; Gupta M; Kumar A; Singh PP; Nargotra A
    J Chem Inf Model; 2017 Aug; 57(8):1957-1969. PubMed ID: 28723151
    [TBL] [Abstract][Full Text] [Related]  

  • 79. Structural Basis of the Interaction of Cyclin-Dependent Kinase 2 with Roscovitine and Its Analogues Having Bioisosteric Central Heterocycles.
    Nekardová M; Vymětalová L; Khirsariya P; Kováčová S; Hylsová M; Jorda R; Kryštof V; Fanfrlík J; Hobza P; Paruch K
    Chemphyschem; 2017 Apr; 18(7):785-795. PubMed ID: 28128514
    [TBL] [Abstract][Full Text] [Related]  

  • 80. Theoretical studies on the selective mechanisms of GSK3β and CDK2 by molecular dynamics simulations and free energy calculations.
    Zhao S; Zhu J; Xu L; Jin J
    Chem Biol Drug Des; 2017 Jun; 89(6):846-855. PubMed ID: 27863047
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.